Emily Clarke

Emily Clarke

Auto-generated profile, based on publicly available information

Emily Clarke

King’s College London, Institute of Psychiatry, Psychology and Neuroscience, Wolfson Centre for Age-Related Disease, Guy’s Campus, London SE1 1UL, UK

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2020 in The American Journal of Geriatric Psychiatry
Verified
Journal Article
Closed access
ARAnto P. Rajkumar
Anto P. Rajkumar
GBGholamreza Bidkhori
Gholamreza Bidkhori
SSSaeed Shoaie
Saeed Shoaie
ECEmily Clarke
Emily Clarke
HMHamilton Morrin
Hamilton Morrin
DADag Aarsland
Dag Aarsland

24 June 2022 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
ECEmily Clarke
Emily Clarke
PSPawel Stocki
Pawel Stocki
ESElizabeth H. Sinclair
Elizabeth H. Sinclair
AGAziz Gauhar
Aziz Gauhar
EFEdward J. R. Fletcher
Edward J. R. Fletcher
JRJ. Lynn Lynn Rutkowski
J. Lynn Lynn Rutkowski
Single domain shark antibodies that bind to the transferrin receptor 1 (TfR1) on brain endothelial cells have been used to shuttle antibodies and other cargos across the blood brain barrier (BBB) to the brain. For these studies the TXB4 brain shuttle was fused to a TrkB neurotrophin receptor agonist antibody. The TXB4-TrkB fusion retained potent agonist activity at its cognate receptor and after systemic administration showed a 12-fold increase in brain levels over the unmodified antibody. Only the TXB4-TrkB antibody fusion was detected within the brain and localized to TrkB positive cells in the cortex and tyrosine hydroxylase (TH) positive dopaminergic neurons in the substantia nigra pars compacta (SNc), where it was associated with activated ERK1/2 signaling. When tested in the 6-hydroxydopamine (6-OHDA) mouse model of Parkinson’s disease (PD), TXB4-TrkB, but not the unmodified antibody, completely prevented the 6-OHDA induced death of TH positive neurons in the SNc. In conclusion, the fusion of the TXB4 brain shuttle allows a TrkB agonist antibody to reach neuroprotective concentrations in the brain parenchyma following systemic administration.

1 October 2019 in Neurochemistry International
Verified
Journal Article
Closed access
ECE. Clarke
E. Clarke
CJC. Jantrachotechatchawan
C. Jantrachotechatchawan
YBY. Buhidma
Y. Buhidma
MBM. Broadstock
M. Broadstock
LYL. Yu
L. Yu
PFP.T. Francis
P.T. Francis

12 March 2020 in bioRxiv
Verified
Preprint
Open access
PDF file
ECEmily Clarke
Emily Clarke
LSLiz Sinclair
Liz Sinclair
EFEdward J R Fletcher
Edward J R Fletcher
AKAlicja Krawczun-Rygmaczewska
Alicja Krawczun-Rygmaczewska
SDSusan Duty
Susan Duty
FWFrank S. Walsh
Frank S. Walsh
Single domain shark antibodies that bind to the transferrin receptor 1 (TfR1) on brain endothelial cells can be used to shuttle antibodies and other cargos across the blood brain barrier (BBB). We have fused one of these (TXB4) to differing regions of TrkB and TrkC neurotrophin receptor agonist antibodies (AAb) and determined the effect on agonist activity, brain accumulation and engagement with neurons in the mouse brain following systemic administration. The TXB4-TrkB and TXB4-TrkC fusion proteins retain agonist activity at their respective neurotrophin receptors and in contrast to their parental AAb they rapidly accumulate in the brain reaching nM levels following a single IV injection. Following SC administration, the most active TrkB fusion protein, TXB4-TrkB 1 , associates with and activates ERK1/2 signalling in TrkB positive cells in the cortex and tyrosine hydroxylase (TH) positive dopaminergic neurons in the substantia nigra pars compacta (SNc). When tested in the 6-hydroxydopamine (6-OHDA) mouse model of Parkinson’s disease (PD) TXB4-TrkB 1 , but not the parental TrkB AAb or a TXB4-TrkC 1 fusion protein, completely prevented the 6-OHDA induced death of TH positive neurons in the SNc. In conclusion, the fusion of the TXB4 TfR1 binding module allows a TrkB AAb to reach neuroprotective concentrations in the brain parenchyma following systemic administration.